inactiv
vaccin
typic
incorpor
adjuv
substanc
enhanc
quantiti
qualiti
cellular
humor
immun
respons
gener
antigen
includ
vaccin
nanoparticl
provid
adjuv
activ
enhanc
deliveri
antigen
immun
system
potenti
innat
immun
respons
fig
discuss
nanotechnolog
section
fig
tabl
nanotechnolog
improv
vaccin
effici
viruslik
particl
vlp
novarti
use
decad
wherea
other
still
earli
stage
develop
vlpbase
vaccin
vlp
divers
highli
versatil
nanoparticl
nm
size
use
vaccin
infecti
diseas
cancer
tabl
recent
vlp
use
vaccin
aim
protect
chronic
diseas
inflammatori
basi
hypertens
alzheim
diseas
rheumatoid
arthriti
also
vaccin
drug
vlp
use
vaccin
broadli
divid
two
class
one
class
vlp
compris
viral
protein
subunit
form
viral
capsid
natur
anoth
class
synthet
vlp
deriv
chemic
synthesi
predesign
subunit
describ
vlp
distinguish
virus
absenc
genet
materi
inabl
replic
undergo
genet
recombin
differ
envelop
nonenvelop
vlp
current
preclin
clinic
vlp
produc
either
without
modif
genet
engin
viral
capsid
subunit
bioconjug
viral
capsid
subunit
antigen
peptid
ligand
sitedirect
mutagenesi
intact
vlp
creat
function
scaffold
multival
surfac
present
antigen
structur
incorpor
vlp
tolllik
receptor
tlr
ligand
celltarget
moieti
biolog
activ
mediat
augment
vaccin
efficaci
human
clinic
trial
vlp
load
synthet
atyp
cpgoligonucleotid
cpgodn
peptid
epitop
deriv
melanomaassoci
antigen
melanoma
antigen
recogn
cell
shown
activ
multifunct
central
memori
cell
cytotox
lymphocyt
ctl
produc
tumour
necrosi
tnf
sever
advantag
use
vlp
nanoparticl
vaccin
relat
uniqu
nanodimension
size
symmetr
shape
uniform
stabl
structur
assembl
nanoparticl
close
resembl
nativ
virus
nanoparticl
use
enabl
preferenti
uptak
vaccin
antigen
antigenpres
cell
apc
notabl
smaller
nanoparticl
nm
size
penetr
tissu
barrier
traffic
drain
lymph
node
rapidli
larger
nanoparticl
greater
nm
size
typic
retain
cell
site
inject
need
taken
traffick
dendrit
cell
dc
facilit
transport
lymph
fig
smaller
nanoparticl
might
lead
effect
activ
adapt
immun
combin
specif
celltarget
strategi
nanoparticl
also
seem
effect
microparticl
enhanc
antigen
uptak
cell
immun
system
exampl
nanoparticl
microparticl
coat
dcspecif
nonintegrin
dcsign
also
known
specif
monoclon
antibodi
target
dc
dcsigncoat
nanoparticl
effect
target
dc
mix
popul
human
blood
cell
wherea
dcsigncoat
microparticl
endocytos
nonspecif
furthermor
wherea
extracellular
protein
taken
dc
process
present
via
mhc
class
ii
pathway
uptak
nanoparticl
vlp
promot
dc
activ
present
antigen
mhc
class
mhc
class
ii
molecul
importantli
lead
prime
antigenspecif
fig
two
prophylact
vlpbase
vaccin
licens
worldwid
one
prevent
hepat
b
viru
hbv
infect
associ
risk
hepatocellular
prevent
human
papillomaviru
hpv
infect
sequela
cervic
use
recombin
protein
engin
selfassembl
vlp
recombin
hbv
vaccin
major
advanc
safeti
plasmabas
hbv
vaccin
howev
first
gener
vlpbase
vaccin
requir
adjuv
optim
immunogen
healthi
individu
highli
effect
highrisk
popul
immunosuppress
patient
elderli
individu
addit
hbv
vaccin
highli
effect
prophylact
vaccin
ineffect
therapeut
vaccin
formul
hbv
vaccin
aluminium
alum
adjuv
major
limit
respect
effect
induct
cellmedi
immun
chronic
hepat
b
alum
predominantli
activ
helper
type
immun
hpv
vaccin
recent
develop
use
monophosphoryl
lipid
mpl
ad
alum
adjuv
induc
immun
respons
ctl
associ
antivir
although
current
vlpbase
vaccin
prophylact
efficaci
limit
use
therapeut
applic
vaccin
excel
safeti
recombin
hbv
vaccin
licens
sinc
hundr
million
dose
administ
worldwid
pitfal
advanc
new
technolog
novel
adjuv
enhanc
immun
respons
includ
potenti
risk
induc
rare
seriou
advers
reaction
becom
evid
evalu
hundr
thousand
individu
concern
induct
autoimmun
diseas
includ
multipl
sclerosi
syndrom
rheumatoid
arthriti
follow
vlpbase
vaccin
rais
systemat
review
associ
multipl
sclerosi
hepat
b
vaccin
studi
report
associ
author
review
conclud
insuffici
evid
modifi
vaccin
schedul
call
addit
studi
carri
vlp
emerg
nanoparticlebas
technolog
provid
new
strategi
enhanc
induct
potent
longlast
potenti
broadli
reactiv
multiclad
neutral
humor
cellular
immun
respons
crucial
achiev
protect
therapi
chronic
infect
rapidli
mutat
pathogen
influenza
latestag
malign
diseas
discuss
benefit
must
balanc
real
perceiv
risk
use
vaccin
high
benefit
public
health
achiev
synthet
vlp
develop
fulli
synthet
vlp
use
chemic
synthes
lipopeptid
enhanc
nanoparticl
assembl
stabil
threedimension
conform
structur
protein
antigen
provid
intrigu
vaccin
strategi
stimul
neutral
antibodi
contrast
envelop
vlp
limit
low
env
densiti
per
selfassembl
peptid
nanoparticl
sapn
describ
synthet
approach
requir
recombin
dna
technolog
express
purif
monom
protein
produc
cell
lipopeptidebas
synthet
vlp
nm
size
use
repetit
display
peptidemimet
epitop
deriv
loop
ref
engin
epitop
design
model
stabl
threedimension
conform
form
bind
broadli
crossneutr
human
monoclon
antibodi
antigen
synthet
vlp
also
incorpor
univers
th
cell
immunogen
peptid
promiscu
bind
multipl
differ
mhc
class
ii
molecul
improv
induct
th
cell
tripalmitoylsglyceryl
cystein
lipid
moieti
induc
activ
interestingli
immun
new
zealand
white
rabbit
synthet
vlp
alon
induc
product
neutral
antibodi
envelop
protein
multipl
thu
structur
vaccinolog
strategi
immunogen
combin
repetit
antigen
display
use
nanoparticlebas
technolog
vaccin
platform
might
enabl
induct
respons
poorli
access
conserv
neutral
epitop
rather
readili
access
immunodomin
nonneutr
epitop
express
nativ
respons
poorli
access
epitop
requir
overcom
extraordinari
mutat
rate
diversif
cours
infect
prevent
viral
escap
design
synthet
nanoparticl
incorpor
lipid
moieti
conform
stabil
protein
antigen
membraneproxim
extern
region
also
great
interest
certain
broadli
reactiv
antibodi
interfer
envmedi
viral
membran
fusion
shown
engag
membran
lipid
protein
contribut
nativ
antigen
structur
interact
potenti
enabl
gener
improv
protect
immun
respons
vaccin
final
new
design
strategi
nanoparticlebas
vaccin
need
focu
immun
respons
conserv
ctl
epitop
cellmedi
immun
respons
togeth
broadli
neutral
antibodi
associ
initi
control
infect
viral
nanoparticlebas
vaccin
carrier
sever
differ
type
nanoparticl
use
either
alon
vaccin
carrier
entrap
antigen
togeth
agent
human
dcspecif
immunomodul
enabl
target
antigen
deliveri
activ
exampl
nanoparticl
use
vaccin
carrier
includ
biodegrad
poli
lactidecoglycolid
plga
nanoparticl
copolym
hydrogel
nanogel
cholesterolbear
hydrophob
pullulan
chp
cation
liposom
polym
use
nanotechnolog
nanoparticl
nanospher
nanocapsul
vaccin
carrier
compos
plga
extens
character
anim
model
wide
use
clinic
applic
matrix
encapsul
codeliv
gradual
releas
activ
vaccin
develop
pegyl
plga
nm
size
use
encapsul
hepat
b
surfac
antigen
hbsag
promot
rapid
uptak
endosom
local
vaccin
antigen
dc
well
subsequ
product
high
titr
antigenspecif
thermosensit
biodegrad
hydrogel
consist
monomethoxi
form
pegyl
plga
less
nm
size
recent
use
mice
achiev
subcutan
deliveri
hbsag
inject
site
time
local
sustain
releas
granulocytemacrophag
colonystimul
factor
gmcsf
crucial
cytokin
surviv
differenti
matur
vaccin
enhanc
recruit
dc
precursor
cell
site
inject
promot
matur
migrat
dc
local
drain
lymph
node
follow
strong
induct
hbsagspecif
antibodi
cell
respons
even
mice
normal
gener
immun
respons
hbsag
low
concentr
hbsag
use
importantli
suggest
adjuv
could
potenti
use
vaccin
incorpor
poorli
immunogen
antigen
vaccin
individu
impair
immun
system
abil
protect
antigen
bioactiv
mediat
maintain
nativ
conform
compon
site
immun
challeng
creat
depot
effect
gradual
local
releas
antigen
time
key
advantag
type
nanoparticl
biodegrad
nanoparticl
also
shown
safe
biocompat
use
vaccin
sapn
uniqu
properti
certain
microbi
pathogen
vlp
inspir
guid
systemat
model
design
manufactur
novel
nanoparticl
use
combin
natur
occur
synthet
engin
biostructur
motif
optim
immun
respons
vaccin
antigen
sapn
construct
differ
protein
oligomer
domain
design
achiev
repetit
antigen
fig
custom
recombin
construct
express
escherichia
coli
encod
singl
polypeptid
chain
two
differ
link
protein
oligomer
domain
contain
particular
coiledcoil
heptad
repeat
pattern
drive
self
assembl
purifi
monom
nanoparticl
approxim
nm
diamet
nanoparticl
icosahedr
symmetri
analog
viral
capsid
thu
sapn
provid
repeat
scaffold
structur
enabl
conform
present
insert
protein
epitop
domain
highli
expos
configur
protrud
extend
surfac
particl
assembl
approxim
peptid
chain
assembl
singl
nanoparticl
form
icosahedr
structur
geometri
enabl
manipul
nearli
paramet
describ
necessari
vlp
scaffold
antigen
display
cellular
activ
lead
substanti
increas
specif
product
hightitr
highaffin
antibodi
direct
insert
linear
conform
antigen
sapn
produc
insert
rang
differ
antigen
includ
hydrophob
looppeptid
epitop
actin
success
induc
product
antibodi
poorli
antigen
phylogenet
conserv
incorpor
trimer
coiledcoil
epitop
surfac
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
sapn
shown
strongli
induc
product
virusspecif
neutral
antibodi
immun
mice
addit
insert
tetramer
form
immunogen
epitop
extern
domain
avian
influenza
viru
matrix
protein
sapn
led
highdens
display
oligomer
epitop
nativ
conform
subsequ
reduct
virusshed
immun
chicken
furthermor
integr
tandem
repeat
immunodomin
b
cell
epitop
malaria
parasit
plasmodium
berghei
circumsporozoit
protein
csp
sapn
induc
product
celldepend
highavid
antibodi
mice
without
use
adjuv
protect
mice
primari
longterm
secondari
challeng
live
sporozoit
without
caus
interestingli
modif
sapn
vaccin
incorpor
b
cell
cell
epitop
deriv
csp
human
malaria
parasit
plasmodium
falciparum
induc
product
hightitr
antibodi
longliv
polyfunct
produc
central
memori
cell
protect
mice
lethal
dose
transgen
p
berghei
malaria
parasit
express
csp
p
final
domain
locat
membraneproxim
extern
region
incorpor
sapn
scaffold
recapitul
epitop
recogn
preexist
antibodi
howev
approach
unsuccess
induc
antibodi
immun
nanoemuls
nanoemuls
adjuv
oilinwat
emuls
compos
solvent
surfact
exampl
nanoemuls
consist
squalen
oil
combin
polysorb
tween
sorbitan
trioleat
span
licens
europ
clinic
vaccin
adjuv
influenza
intramuscularli
administ
ten
million
healthi
adult
elderli
individu
adjuv
activ
seem
involv
combin
mechan
includ
increas
cellular
uptak
antigen
enhanc
releas
cytokin
chemokin
recruit
monocyt
granulocyt
site
intramuscular
inject
augment
matur
upregul
ccchemokin
receptor
antigenprim
dc
promot
migrat
drain
lymph
shown
potent
adjuv
alum
induc
broadli
protect
humor
cellmedi
immun
furthermor
respect
vaccin
pandem
influenza
virus
exampl
promot
protect
antivir
immun
respons
deliv
rel
low
dose
virusderiv
antigen
contrast
deliveri
similar
antigen
dose
combin
alum
result
variabl
ineffect
antivir
clinic
experi
use
document
clinic
studi
well
postmarket
surveil
increas
reactogen
includ
inject
site
pain
describ
follow
administr
attribut
increas
inflamm
associ
enhanc
immun
respons
ratio
increas
reactogen
benefit
increas
immun
remain
favour
especi
enhanc
respons
need
case
pandem
influenza
earlystag
clinic
trial
current
progress
studi
efficaci
adjuv
vaccin
viral
pathogen
includ
herp
simplex
viru
hbv
intranas
administr
enhanc
serum
antibodi
respons
naiv
mice
preinfect
nanoemuls
compos
soybean
oil
oppos
squalen
shown
anim
model
recent
human
augment
target
vaccin
antigen
immun
system
safe
induc
potent
mucos
humor
cellular
immun
respons
intranas
adjuv
activ
mixtur
primarili
depend
retent
nanodroplet
structur
emuls
posit
charg
facilit
bind
neg
charg
protein
mucin
nanoscal
size
posit
emuls
enabl
penetr
mucou
layer
bind
cell
membran
cellular
uptak
togeth
mediat
induct
innat
adapt
immun
cytokin
secret
ciliat
epitheli
cell
nasal
mucosa
cell
nasalassoci
lymphoid
tissu
nalt
follow
activ
migrat
antigenprim
also
known
dc
region
lymph
interestingli
nanoemuls
shown
induc
necrosi
apoptosi
epitheli
cell
simultan
activ
surfac
express
calreticulin
signal
immunogen
cell
observ
consist
mechan
nanoemuls
rapidli
facilit
engulf
die
antigenload
epitheli
cell
dc
phagocyt
cell
nanoemuls
broad
antimicrobi
activ
envelop
virus
bacteria
use
inactiv
well
provid
adjuv
activ
vaccin
prepar
involv
intact
virus
vaccinia
respiratori
syncyti
viru
rsv
influenza
singleantigen
formul
includ
kda
outer
membran
lipid
protein
ompa
polypeptid
burkholderia
anthrax
protect
envelop
protein
ref
hepat
b
surfac
also
use
adjuv
nanoemuls
shown
littl
toxic
extens
test
multipl
seriou
advers
effect
human
although
intranas
administ
nanoemuls
evalu
less
individu
particularli
relev
histori
intranas
administ
adjuv
includ
associ
cranial
nerv
vii
palsi
also
known
bell
palsi
nasal
administr
influenza
virosom
togeth
e
coli
heat
labil
toxin
mucos
although
evid
intranas
administ
nanoemuls
adjuv
undergo
retrograd
transport
associ
cranial
nerv
vii
palsi
vigil
monitor
side
effect
other
continu
throughout
clinic
develop
programm
licens
cation
liposom
cation
liposom
typic
rang
particl
diamet
nm
depend
formul
use
vaccin
adjuv
deliveri
system
encapsul
protect
enabl
antigen
uptak
prolong
activ
profession
cation
charg
composit
lipid
compon
essenti
effici
antigen
adsorpt
nanoparticl
prepar
vaccin
retent
site
inject
innat
activ
immun
accessori
cell
vaccin
immunogen
includ
induct
cellular
differ
cation
lipid
incorpor
formul
includ
quaternari
ammonium
compound
exampl
dimethyl
dioctadecyl
ammonium
bromid
dda
dotap
cholesterol
deriv
exampl
dimethylaminoethanecarbamoylcholesterol
imidazolium
compound
exampl
oleoyloxi
ethyl
imidazolinium
chlorid
dotim
compound
immunostimul
trehalos
dibehen
tdb
synthet
analogu
trehalos
dimycol
engag
tlrindepend
pathway
innat
compon
systemat
use
optim
adjuv
activ
improv
type
qualiti
magnitud
cellular
humor
respons
differ
diseas
model
applic
cation
liposom
also
shown
enhanc
efficaci
reduc
system
toxic
immunostimul
includ
mpl
tlr
differ
cation
liposom
incorpor
immunostimul
vaccin
antigen
current
evalu
human
clinic
trial
test
safeti
efficaci
infecti
diseas
taken
togeth
studi
show
strike
rang
applic
safeti
divers
type
nanoparticl
fig
use
nanoemuls
nanogel
liposom
induc
potent
immun
respons
differ
antigen
includ
microorgan
tumour
antigen
tabl
nanoparticl
induc
broad
spectrum
immun
respons
includ
cell
respons
induc
develop
igg
iga
antibodi
system
local
depend
formul
rout
deliveri
fig
studi
indic
differ
nanoparticl
composit
engin
desir
enhanc
immun
respons
mechan
associ
nanoparticl
deliveri
control
releas
antigen
entrap
immunomodul
locat
addit
recruit
target
uptak
antigen
accessori
cell
profession
apc
tabl
addit
stimul
direct
immun
respons
nanotechnolog
therapeut
use
inhibit
detriment
immun
respons
occur
allergi
autoimmun
transplant
reject
immunosuppress
effect
nanotherapeut
discuss
follow
section
fig
tabl
immunosuppress
effect
fulleren
much
work
explor
direct
effect
nanoparticl
immun
respons
come
field
toxicolog
fulleren
shown
direct
immunosuppress
fulleren
molecul
exclus
compos
carbon
commonli
use
nanotechnolog
develop
item
electron
paint
polym
fulleren
global
produc
order
hundr
tonn
per
spheric
fulleren
approxim
nm
diamet
absorb
electron
benzen
ring
surfac
enabl
function
scaveng
reactiv
oxygen
speci
ro
incub
human
mast
cell
peripher
blood
basophil
spheric
fulleren
result
decreas
ige
receptormedi
signal
decreas
product
ro
decreas
degranul
mous
model
anaphylaxi
fulleren
treatment
prevent
histamin
releas
prevent
reduct
bodi
temperatur
normal
occur
mice
allergen
fullerenelik
structur
manufactur
cylind
call
carbon
nanotubul
cnt
typic
diamet
approxim
nm
length
much
sever
micrometr
structur
form
singlewal
multiwal
tube
shown
direct
immunosuppress
effect
mice
expos
singlewal
cnt
pharyng
aspir
increas
level
inflamm
lung
enhanc
recruit
dc
alveolar
macrophag
polymorphonuclear
cell
lymphocyt
interestingli
cultur
stimulatori
dc
prolifer
expans
splenic
cell
popul
decreas
anim
expos
singlewal
cnt
cocultur
experi
dc
expos
lipopolysaccharid
lp
singlewal
cnt
less
capabl
promot
prolifer
expans
cell
popul
dc
expos
lp
although
mechan
respons
effect
singlewal
cnt
dc
function
fulli
elucid
known
mechan
multiwal
cnt
affect
cell
function
anim
expos
inhal
multiwal
cnt
sever
week
show
increas
pulmonari
inflamm
show
system
immun
suppress
form
decreas
cell
prolifer
lower
product
celldepend
gene
express
enzym
cyclooxygenas
also
known
prostaglandin
e
synthas
upregul
spleen
multiwal
cnttreat
mice
respons
abrog
administr
cyclooxygenas
antagonist
mice
overal
immunosuppress
effect
shown
mediat
transform
growth
produc
alveolar
fulleren
direct
immunosuppress
effect
discuss
also
capac
store
deliv
activ
drug
substanc
immunosuppress
properti
although
spheric
fulleren
effici
deliveri
immunosuppress
drug
carbon
nanotubul
use
effect
deliv
compound
proapoptot
protein
cytochrom
nanoparticl
vehicl
immunosuppress
addit
direct
immunosuppress
effect
nanotechnolog
also
use
deliv
drug
known
immunosuppress
activ
exampl
nanocryst
use
increas
water
solubl
bioavail
immunosuppress
drug
use
prevent
transplant
reject
sirolimu
trien
macrolid
immunosuppress
effect
inhibit
proinflammatori
cytokin
owe
poor
solubl
water
initi
formul
sirolimu
oral
solut
mixtur
current
licens
oral
tablet
formul
made
avail
use
nanometres
crystal
gener
use
nanoscal
dendrim
polym
dendrim
molecul
repetit
branch
around
focal
point
similarli
nanocryst
dendrim
encapsul
activ
drug
way
deliv
activ
drug
target
tissu
addit
dendrim
polym
present
target
polyamidoamin
pamam
dendrim
among
best
known
dendrim
compos
diamin
core
react
methyl
acryl
follow
anoth
diamin
result
regular
radial
concentr
layer
gener
give
rise
success
larger
dendrim
pamam
dendrim
report
deliv
nacetyl
cystein
nac
across
blood
brain
barrier
nac
antioxid
antiinflammatori
agent
commonli
use
treat
acetaminophen
poison
mucolyt
basi
work
show
pamam
dendrim
local
activ
microglia
astrocyt
rabbit
cerebr
palsi
nac
conjug
pamam
dendrim
intraven
administ
rabbit
cerebr
palsi
administr
nac
pamam
dendrim
nac
alon
report
decreas
neuroinflamm
improv
motor
exampl
use
pamam
dendrim
immunosuppress
includ
develop
pamam
dendrim
glucosamin
shown
inhibit
inflammatori
respons
scar
tissu
mechanist
studi
shown
pamam
dendrim
glucosamin
block
format
also
known
interf
electrostat
bind
lp
block
entri
lipid
chain
lp
hydrophob
pocket
basi
find
dendrim
glucosamin
test
rabbit
ileal
loop
model
shigella
spp
infect
shown
decreas
proof
concept
decreas
inflamm
model
gastroenter
effect
dendrim
also
studi
use
dendrim
synthes
agonist
interestingli
dendrimer
small
molecul
result
loss
activ
mainten
activ
initi
dosedepend
increas
cytokin
product
follow
decreas
although
mechan
particular
tlr
turn
turn
dendrim
fulli
understood
highlight
possibl
molecular
manipul
nanoscal
level
respect
elucid
modul
innat
immun
respons
therapeut
use
plga
formul
nanoscal
level
use
deliv
immunosuppress
includ
bifunct
peptid
inhibitor
leukaemiainhibitori
factor
lif
addit
betamethason
plga
result
sustain
antiinflammatori
effect
two
anim
model
arthriti
compar
betamethason
bifunct
peptid
inhibitor
simultan
target
mhc
class
ii
molecul
intercellular
adhes
molecul
effect
deliv
use
plga
complex
result
decreas
cytokin
product
suppress
diseas
mice
experiment
autoimmun
plga
also
use
deliv
lif
result
upregul
forkhead
box
express
cell
expans
regulatori
cell
popul
mice
effect
seen
lif
administ
mice
absenc
type
polym
rout
administr
might
also
influenc
whether
enhanc
suppress
immun
respons
neg
charg
plga
compar
posit
charg
ntrimethyl
chitosan
tmc
nanoparticl
increas
humor
immun
respons
ovalbumin
intramuscularli
administ
howev
neg
charg
tmc
increas
humor
immun
respons
ovalbumin
intranas
probabl
due
electrostat
interact
posit
charg
carrier
neg
charg
mucou
shown
occur
carrier
includ
nanoemuls
interestingli
neg
charg
intranas
administ
plga
induc
immunoregulatori
respons
character
enhanc
express
nalt
cervic
lymph
node
decreas
delay
type
hypersensit
respons
increas
result
show
type
polym
charg
rout
administr
influenc
whether
result
immun
respons
enhanc
sln
liposom
micel
lipidbas
nanotechnolog
includ
solid
lipid
nanoparticl
sln
liposom
micel
fig
sln
solid
room
temperatur
bodi
temperatur
wherea
liposom
micel
liquid
temperatur
liposom
vesicl
compos
lipid
bilay
hydrophil
centr
convers
micel
compos
amphiphil
molecul
arrang
oil
water
hydrophob
core
water
oil
hydrophil
core
activ
drug
incorpor
deliv
carrier
chosen
basi
composit
size
addit
carrier
might
target
specif
tissu
use
specif
exampl
liposom
use
carrier
achiev
immunosuppress
includ
bisphosphon
clondron
deplet
pulmonari
macrophag
acut
lung
well
alendron
deplet
circul
monocyt
coronari
arteri
target
liposom
specif
cell
exemplifi
deliveri
small
interf
rna
sirna
dc
surround
liposom
carri
sirna
monoclon
antibodi
specif
dc
genesilenc
approach
use
specif
target
express
dc
result
reduc
level
cell
prolifer
liposometr
micel
also
use
deliv
agent
impair
immun
respons
includ
camptothecin
topoisomeras
inhibitor
origin
use
treatment
cancer
recent
appli
treatment
rheumatoid
arthriti
formul
camptothecin
steric
stabil
micel
ssm
improv
deliveri
antiinflammatori
effect
mous
model
arthriti
studi
vasoact
intestin
peptid
use
target
ssm
cell
macrophag
nanoemuls
immunosuppress
final
exampl
nanotechnolog
appli
suppress
immun
respons
use
nanoemuls
deliv
self
nanoemuls
combin
self
antigen
thyroglobulin
deliv
mice
anim
becom
toler
thyroglobulin
respons
character
reduc
humor
immun
respons
thyroglobulin
upregul
express
increas
regulatori
treg
cell
activ
particularli
interest
administ
foreign
antigen
enhanc
immun
respons
increas
antigen
deliveri
well
increas
signal
pathway
activ
stimul
includ
myeloid
differenti
primaryrespons
gene
tir
domaincontain
adaptor
protein
induc
trif
also
known
pathway
result
product
releas
proinflammatori
much
inflamm
detriment
control
stimul
import
immunoregulatori
function
endotoxin
toler
mechan
immunosuppress
occur
continu
presenc
addit
immunoregulatori
molecul
describ
increas
endotoxin
toler
well
aforement
direct
immunosuppress
effect
indirect
immunosuppress
effect
nanoemuls
deliveri
self
anoth
similar
signal
mechan
nanotechnologymedi
immunosuppress
endotoxin
toler
rel
increas
trif
activ
decreas
trif
bia
describ
particular
agonist
lp
deriv
use
adjuv
numer
vaccin
includ
licens
recombin
hpv
bival
nanotechnolog
current
use
engin
specif
immun
respons
prophylact
therapeut
effect
futur
use
nanoparticl
uniqu
immunolog
properti
determin
size
shape
charg
poros
hydrophob
enabl
research
custom
immun
respons
new
unexpect
way
improv
protect
outbreak
pandem
virus
emerg
mutat
pathogen
requir
rapid
activ
innat
adapt
immun
respons
ideal
within
hour
innat
immun
respons
day
adapt
immun
respons
singl
prime
dose
vaccin
could
achiev
absorpt
nanoparticl
uniqu
combin
antigen
cytokin
also
possibl
passiv
immun
nanoparticledeliv
immunoglobulin
gene
could
produc
antibodi
specif
pathogen
could
provid
immun
replac
rather
simpli
immun
manipul
nanotechnolog
addit
activ
ctl
respons
target
tumour
viral
infect
cell
accomplish
sever
way
use
nanotechnolog
nanoparticl
could
surround
antigen
augment
ctl
activ
could
combin
immunomodul
includ
cytokin
gmcsf
fmsrelat
tyrosin
kinas
ligand
mani
costimulatori
ligand
known
multimer
ligand
glucocorticoidinduc
tnfrrelat
protein
gitr
also
known
activ
block
ligand
could
turn
lymphocyt
greater
precis
antibodi
current
use
help
control
autoimmun
immun
respons
allergen
even
transplant
organ
use
antigen
nodlik
receptor
tlr
ligand
microbi
pattern
recognit
system
could
induc
ctl
respons
antigen
normal
produc
activ
also
possibl
suppress
nanoparticl
could
given
rel
patient
specif
autoimmun
diseas
order
prevent
diseas
develop
genet
screen
mani
immun
diseas
might
enabl
earli
correct
immun
defect
use
nanoparticl
gene
deliveri
method
rather
bone
marrow
transplant
addit
potenti
therapeut
applic
nanotechnolog
recent
advanc
nanotechnologybas
screen
strategi
use
silicon
nanowir
combin
sirna
transcript
profil
time
shown
promis
select
perturb
immun
respons
therefor
facilit
identif
crucial
point
molecular
network
regul
immun
emerg
nanotechnolog
provid
new
way
interrog
complex
pathway
control
differenti
immun
cell
includ
balanc
treg
cell
approach
might
also
enabl
futur
design
effect
therapeut
regul
immun
system
potenti
reduc
side
effect
inflamm
summari
field
nanotechnolog
continu
provid
remark
insight
natur
immun
respons
applic
nanotechnolog
immunolog
might
also
affect
new
strategi
prevent
treatment
human
diseas
